mp.weixin.qq.com·· 7 hours agoScore89
Innovent Announces at 2026 ESMO LBA That IBI343 Met PFS and OS Dual Primary Endpoints in Phase 3 G-HOPE-001 Gastric Cancer Study
In brief
At the 2026 ESMO congress, Innovent announced in a late-breaking abstract that the international multicenter phase 3 G-HOPE-001 study of the CLDN18.2 ADC IBI343 in gastric cancer met both primary endpoints of progression-free survival and overall survival.
Source: mp.weixin.qq.com · mp.weixin.qq.com